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Background: Due to the lack of ERα, triple negative breast cancers (TNBCs) are not susceptible to endocrine therapy
using antiestrogens. However, the majority of TNBCs express the membrane bound estrogen receptor GPR30. We have
recently shown that knock-down of GPR30 expression prevented growth stimulation of TNBC cell lines by 17β-estradiol.
Now we analyzed whether specific inhibition of GPR30 represents a new option for therapy of TNBC.
Methods: Growth of TNBC cells was assessed using Alamar-blue colorimetric assay. Activation of c-Src and EGF-receptor
was assessed using Western blots. Expression of c-fos, cyclin D1 and aromatase was quantified by RT-PCR. Gα-specific
signaling of GPR30 was analyzed by electrophoretic mobility shift assay.
Results: HCC1806 cells showed the highest GPR30 expression, in HCC70 cells it was clearly lower, in MDA-MB-231 cells it
was lowest. 10−8 M 17β-estradiol significantly increased proliferation of HCC1806 cells to 134 ± 12% of control (p < 0.01).
Proliferation of HCC70 cells was slightly increased to 116 ± 8% of control. Estriol significantly reduced cell number of
HCC1806 cells to 16 ± 12% (p < 0.01). Cell number of HCC70 cells and of MDA-MB-231 cells was reduced to 68 ± 25%
and to 61 ± 10%, respectively.
Activity of Src kinase increased to 150 ± 10% (p < 0.05) by 10−8 M 17β-estradiol treatment in HCC1806 and to 220 ± 20%
in HCC70 cells (p < 0.01). Estriol treatment completely inhibited 17β-estradiol-induced p-src activation. Transactivation
of EGF-receptor increased by estradiol treatment to 350% in HCC1806 and to 280% in HCC70 cells. Estriol completely
suppressed EGF-receptor transactivation. c-fos expression increased to 260% and to 190%, respectively. Estriol reduced
this induction to 160% (HCC1806) and below control in HCC70 cells. Cyclin D1 was induced to 290% (HCC1806) and
170% (HCC70) and completely inhibited by estriol. 17β-estradiol increased CREB-phosphorylation to 400%. Binding of
phospho-CREB to a CRE of cyclin D1 was enhanced to 320%.
Conclusion: Specific pharmacological inhibition of GPR30 might become a promising targeted therapy for TNBC
in future.
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Breast cancer is the most frequent cause of mortality from
cancer in women. Therapy of ERα-positive tumors using
anti-estrogens, like Tamoxifen and aromatase inhibitors
achieves an overall survival of about 82% after eight years
[1]. Triple-negative breast cancers (TNBCs) that do not
express ERα and progesterone receptors and do not over-
express Her-2neu gene product are not susceptible to* Correspondence: rainer.girgert@med.uni-goettingen.de
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unless otherwise stated.endocrine therapy. Mortality of patients with TNBC is
double as high as for carriers of ERα-positive tumors [1].
For this reason, there is an urgent need for development
of innovative, targeted therapies for this group of patients.
In the last years a number of new therapeutic approaches
were tested with limited success. Treatment with platinum
compounds resulting in a response rate of 30% could be
increased to 49% by the combination with Cetuximab, an
antibody to the epidermal growth factor receptor [2]. The
DNA-repair enzyme, poly-ADP-ribose polymerase (PARP),
was also found to be a promising target in TNBC [3,4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tor resides at the plasma membrane. G-protein coupled
receptor 30 (GPR30) was identified to be responsible for
most rapid signaling events of 17β-estradiol [5,6]. Before
identification of GPR30 as third kind of estrogen recep-
tors, other authors supposed that rapid estrogen signaling
is initiated by a divergent membrane bound ERα [7].
GPR30 expression is prevalent in TNBC and associated
with a higher recurrence rate [8].
In early experiments, almost before function of GPR30
was described, a rapid increase of cAMP was observed
after stimulation of MCF-7 breast cancer cells with 17β-
estradiol [9]. Only some years later it was discovered,
that binding of 17β-estradiol to GPR30 increases adenylate
cyclase activity and MAP-kinase Erk 1 [6,9,10]. Increased
cAMP leads to phosphorylation of CREB that subsequently
binds to cAMP-response elements (CRE) on promoters of
mitogenic genes [11]. Activation of MAP-kinase finally
leads to enhanced proliferation of breast cancer cells.
The signaling via βγ-subunits in TNBC has been briefly
described [12]. In addition to 17β-estradiol, selective
estrogen receptor modulator Tamoxifen and complete
ERα antagonist Fulvestrant bind to GPR30 and activate
certain signaling pathways in breast cancer cells, thus
leading to stimulation of proliferation [5]. According to
these observations GPR30 has been proposed to be an
excellent new therapeutic target for the treatment of
TNBC [13].
Recently, we reported that in TNBC cell lines an increase
of proliferation by17β-estradiol was dependent on GPR30,
as it was completely prevented by knock-down of GPR30
expression using specific siRNA [12].
Dennis et al. developed G15, a specific inhibitor of
GPR30 signaling [14]. In addition, estriol has been shown
to be a potent inhibitor of GPR30 [15]. In this report we
have analyzed the efficacy of estriol as inhibitors of GPR30
on growth inhibition of TNBC cells. Similar attempts
using G15 in TNBC were less successful than with estriol
and are additionally presented as supplementary material.
Methods
Cell lines, chemicals and cell culture
TNBC cell lines HCC1806, HCC70 and MDA-MB-231
were obtained from American Type Culture Collection
(ATCC, Manassas, Virginia, USA). In order to guarantee
the identity of the cell lines over the years, cells were
expanded after purchase and aliquots were stored in
liquid nitrogen. Every half year a new frozen stock was
opened and expanded to carry out the experiments. Cells
were cultured in MEM (Biochrom, Berlin, Germany)
supplemented with 2 mM glutamine, 6 ng/ml insulin,
10 ng/ml transferrin, penicillin (50 U/ml), streptomycin
(50 μg/ml) from Gibco (Paisley, UK), and 5% fetal bovine
serum (Biochrom, Berlin).17β-estradiol (E2), estriol, insulin, and transferrin were
from Sigma-Aldrich (Deisendorf, Germany). G15 was
purchased from R & D systems (Wiesbaden, Germany).
Primers for PCR and biotin-labeled oligonucleotide probes
for electrophoretic mobility shift assay were produced by
MWG-eurofins (Ebersberg, Germany).
Proliferation assays
Proliferation assays for 17β-estradiol in the absence and in
the presence of estriol were performed in phenol red-free
medium supplemented with charcoal depleted serum
(CD-FCS) as previously described [16]. CD-FCS was
prepared according to the procedure described by Stanley
et al. [17].
Proliferation assays were performed at least three
times in quadruplicates with different passages. Means
and standard deviations of the optical density (OD) of
the replicates were calculated.
Treatment of cells
For stimulation of TNBC cells to analyze signal transduc-
tion of GPR30, 4×106 cells were plated in culture medium
into 25 cm2-culture flasks. After attachment, cells were
serum starved for 24 hours to synchronize the 17β-
estradiol-starved cells in G0-phase. Serum starved cells
were treated for 30 minutes either with 10−4 M estriol or
solvent (0.1% ethanol) and subsequently stimulated with
10−8M 17β-estradiol in 0.1% ethanol for 10 min or 20 mi-
nutes. Cells were harvested and cell pellets lysed in 100 μl
Cell lytic M (Sigma, Deisendorf, Germany), supplemented
with protease-inhibitor (Sigma, Deisendorf, Germany) and
phosphatase-inhibitor (Sigma, Deisendorf, Germany).
Western blots
Lysates of cells were cleared at 15000 g for 5 minutes
and the protein concentration in the supernatant was
determined using the method of Bradford. 50 μg of each
sample were separated in a 7.5% polyacrylamid gel, blotted
on PVDF-membrane and sequentially detected with
rabbit-anti-human primary antibodies. GPR30 expression
was detected with anti-GPR30 (sc-48524) from Santa Cruz
(Dallas, TX), anti-phospho-Src (2113), anti-Src (2109),
anti-S133phospho-CREB (9198), were all purchased from
Cell Signaling and anti-CREB (04-767) from Millipore.
Antibody to phospho Tyr1173EGF-receptor (324864) was
from Calbiochem (Darmstadt, Germany), anti-EGF-receptor
antibody (2235) from Epitomics (Hamburg, Germany) and
anti-actin from Sigma Chemicals (Deisendorf, Germany).
All primary antibodies were used diluted 1:2000 in TBST.
After washing in TBST blots were incubated with a
1:20.000 dilution of horseradish peroxidase conjugated
goat-anti-rabbit antibody (ECL, GE-Healthcare, Freiburg,
Germany). After washing, blots were incubated with the
chemoluminescence reagent Femto (Thermo-Scientific,
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minescence detector (Licor, Lincoln, NE). Densitometric
evaluations of the protein bands were performed using
the analysis tool of the Image Studio Digits Vers.4 deliv-
ered with the Licor C-Digit chemoluminescence detector
(Licor, Lincoln, NE) and were normalized to actin.Analysis of GPR30 signaling
GPR30 signal transduction and gene expression of c-fos,
cyclin D1 and aromatase were analyzed as previously
described [12].
In detail, from TNBC cells, pretreated with estriol or not
and subsequently stimulated for 30 minutes with 10−8M
17β-estradiol, RNA was purified using the RNeasy-kit
(Qiagen, Hilden, Germany).
200 ng of each RNA were transcribed using 400 u
Superscript reverse transcriptase (Invitrogen, Karlsruhe,
Germany) in the presence of 0.5 μM oligo-dT primer for
60 min at 37°C. 5 μl of the resulting cDNA were amplified
with 1 u Taq polymerase (Peqlab, Erlangen, Germany) in
the presence of 200 μM dNTPs and 200 nM of the appro-
priate primers described in [12].
Optimal PCR conditions for each gene were ascertained,
guaranteeing that generation of the PCR-products was
in the exponential phase. Therefore cDNA of c-fos was
amplified by 32 cycles, cyclin D1 by 35 cycles, and aroma-
tase by 28 cycles. As reference the RNA of the ribosomal
protein L7 was amplified by 20 cycles.
PCR-products were separated in a 2% agarose gel
(Type IV, special high EEO, Sigma Chemicals, Steinheim,
Germany) in 0.5x TBE buffer at 100 V for 30 min. Gels
were stained in ethidium bromide (2 μg/ml) for 30 min
and photographed on a transiluminator using a CDS
camera (TD20, Kodak, Rochester).HCC70    1806   MDA231
GPR30
Actin
rel.Electrophoretic mobility shift assay
The effects of estriol on the downstream signaling of
GPR30 were analyzed using an electrophoretic mobility
shift assay (EMSA) as previously described [18] using
oligonucleotides representing the promoter sequence
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Figure 1 GPR30 expression in TNBC cell lines used. 10 μg protein
extracts of HCC70-, HCC1806- and MDA-MB-231-cells were separated
in a polyacrylamide gel and Western-blots were sequentially analyzed
using antibodies against GPR30 and actin (house-keeping gene).
GPR30 expression was determined by densitometry of the bands
giving the relative expression in each cell line.Statistical analysis
The data were tested for significant differences by one-way
analysis of variance followed by Student–Newman–Keuls’
test for comparison of individual groups, after a Bartlett test
had shown that variances were homogenous.Results
Comparison of GPR30 expression in triple-negative breast
cancer cell lines
Protein extracts of three different TNBC cell lines were
analyzed on Western-blots for expression of GPR30
(Figure 1). We proved specifity of the used antibody by
knocking down GPR30 with siRNA in HCC1806 and
HCC70 [12]. GPR30 was most prominent in HCC1806
cells. HCC70 cells expressed about 85% of the amount of
GPR30 detected in HCC1806. Using immunohistochemis-
try TNBC cell line MDA-MB-231 presented as GPR30
negative [19], but our Western-blot analysis revealed
traces of GPR30 protein in this cell line accounting for
26% of the amount present in HCC1806 (Figure 1).
Stimulation of cell proliferation by 17β-estradiol in TNBC
cells is prevented by estriol
The effects of 17β-estradiol and estriol on proliferation
of TNBC cell lines with high-level GPR30 expression
(HCC1806) and low-level GPR30 expression (MDA-MB-
231) were analyzed over a concentration range between
of 10−12 M and 10−6 M 17β-estradiol (Figure 2A and B)
and with estriol between 10−6 M and 8x10−5 M (Figure 2C
and D). Cell number of the TNBC cell line HCC1806
slightly increased in the presence of increasing concentra-
tions of 17β-estradiol reaching a plateau of 130% between
10−10 M and 10−8 M estradiol. Even in charcoal stripped
medium without estradiol HCC1806 cells proliferated,
due to growth factors present in the charcoal stripped
serum (Additional file 1). In MDA-MB-231 cells, reported
to be negative for GPR30, there was no significant eleva-
tion of cell number observed at any of the tested estradiol
concentrations (Figure 2B). The traces of GPR30 detected
on Western-blot of MDA-MB-231 (Figure 1) were not
sufficient for 17β-estradiol to increase cellular growth of
this TNBC cell line. With increasing concentrations estriol
reduced cell number of 17β-estradiol stimulated HCC1806
Figure 2 Impact of 17β-estradiol and estriol on proliferation of TNBC cells. Cells of a GPR30 positive (HCC1806) and a GPR30 negative TNBC
cell line (MDA-MB-231) were grown for 7 days in culture medium supplemented with charcoal-treated FCS either in the presence of 10−12 M to
10−6 M 17β-estradiol (A and B) or 10−6 M to 8×10−5 M estriol (C and D). Cell number was evaluated in microwell plates by a colorimetric assay
using Alamar blue. Optical densities (OD) measured in the non-stimulated wells (control) were set 100%. The ODs estimated in the stimulated
wells were divided by the average value of the control wells to give the relative cell number in % of control achieved under the indicated
conditions. (a) p < 0.05 vs. control; (b) p < 0.01 vs. control. Data are mean values and SE of three independent experiments with four replicates.
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whereas in MDA-MB-231 cells expressing only low
amounts of GPR30 cell number was reduced to only
61 ± 10% at the highest applied concentration. In
HCC70 cells expressing less GPR30 than HCC1806
(Figure 1) the reduction of cell number was lower to
68 ± 25% (Data not shown).
To evaluate the inhibitory activity of estriol in the
presence of 17β-estradiol growth of TNBC cells was
treated either with 17β-estradiol alone or in combination
with 10−4 M estriol (Figure 3A and B). Cell number of
HCC1806 cells increased at 10−8 M 17β-estradiol to
127 ± 8% of control. In cells pretreated with 10−4 M estriol
cell number significantly decreased to 54 ± 7% of control
(p < 0.05) despite stimulation with 10−8M 17β-estradiol
(Figure 3A). In cell line HCC70 10−8 M 17β-estradiol
increased cell number to 116% of control, co-treatment
with 10−4 M estriol significantly decreased cell number to
64% of control (p < 0.01) (Figure 3B). Estriol clearly pre-
vented the stimulation of proliferation by 17β-estradiol in
both TNBC cell lines. Antiproliferative effects of estriol
paralleled the amount of GPR30 expressed in the various
cell lines (Figure 1).Estriol inhibits GPR30 dependent transactivation of
EGF-receptor
In order to explain the effects of estriol on proliferation
of TNBC cells activation of c-src and EGF-receptor by
10−8 M 17β-estradiol in the absence and in the presence of
10−4 M estriol was analyzed. In serum-starved HCC1806
cells phosphorylation of c-src at Tyr416 was detectable.
Activation of c-src was maximal after 5 minutes of stimu-
lation with 10−8 M 17β-estradiol (Figure 4) and decreased
after 15 minutes of stimulation (not shown). Activation of
p-src increased to 150 ± 10% (p < 0.05) after 5 minutes
stimulation with 17β-estradiol (Figure 4A, lane 2). In
HCC70 cells p-src increased to estimated 220 ± 20% of
control (p < 0.01) (Figure 4B, lane 2). In HCC1806 cells
pretreated for 30 minutes with 10−4 M estriol activation
of src-kinase by 17β-estradiol was completely blocked
(Figure 4A, lane 4); in HCC70 cells after pretreatment
with estriol no p-src activation by 10−8 M 17β-estradiol
could be observed (Figure 4B, lane 4).
Activation of EGF-receptor downstream of p-src was
increased to 350 ± 160% (p < 0.01) in HCC1806 cells by
17β-estradiol (HCC70: 280 ± 80%, p < 0.01). Pretreatment
of the cells with 10−4 M estriol completely prevented
A B
Contr C   10-4M E3      C    10-4M E3
10-9M E2             10-8M E2      
Contr C    10-4M E3      C     10-4M E3
10-9M E2             10-8M E2      
Figure 3 Comparison of the inhibitory effect of estriol on the proliferative effect of 17β-estradiol on TBNC cells. Cells of two GPR30
expressing TNBC cell lines (A) HCC1806, (B) HCC70 were stimulated with 10−9 M E2 or 10−8 M E2 in the absence or presence of 10−4 M E3. Cell
number was evaluated using Alamar blue. ODs estimated in stimulated wells were divided by the average value of the control wells to give the
relative cell number in % of control achieved under the indicated conditions. (c) p < 0.01 vs. control; (d) p < 0.001 vs. 10−9 M E2 w/o E3; (e) p < 0.01 vs.
control; (f) p < 0.001 vs.10−8 M E2 w/o E3; (g) p < 0.01 vs. 10−9 M E2 w/o E3; (h) p < 0.05 vs. 10−8 M E2 w/o E3. Data are mean values and SE of three
independent experiments with four replicates.
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lines (Figure 4A and B, lane 4).
Estriol prevents induction of c-fos expression by
17β-estradiol
Following activation of EGF-receptor the growth pro-
moting signal is forwarded via MAP-kinase Erk to the
nucleus where finally expression of c-fos is induced.
Serum-starved cells of two different TNBC cell lines
(HCC1806 and HCC70) were stimulated for 30 minutes
with 10−8 M 17β-estradiol. mRNA of these cells was
analyzed for c-fos expression by RT-PCR and expression of
c-fos was compared to the expression in non-stimulated
cells (Figure 5). Stimulation by 10−8 M 17β-estradiol most
strongly increased c-fos expression in HCC1806 cells to
260 ± 20% (p < 0.001) (Figure 5A, lane 2). In HCC70 cells
stimulated with17β-estradiol c-fos expression accounted
for 190 ± 70% of control (Figure 5B, lane 2). If the HCC
1806 cells were pretreated with 10−4 M estriol for two
hours 17β-estradiol increased c-fos expression only
to160 ± 3% (p < 0.01). In HCC70 cells pretreated with
estriol the increase of c-fos expression by 17β-estradiol
was attenuated below control value.
Induction of cyclin D1 expression by 17β-estradiol is
inhibited by estriol
Cyclin D1 is necessary for transfer of cells from G1-phase
to S-phase of cell cycle and a prerequisite for proliferation.
Therefore, cyclin D1 expression was analyzed in TNBC cell
lines after stimulation of the cells with 10−8 M 17β-estradiol
for 30 minutes (Figure 5A and B, lane 2). In HCC1806 cells
17β-estradiol increased cyclin D1 expression to 300 ± 30%
of control (p < 0.05) and estriol completely prevented acti-
vation of cyclin D1 expression (Figure 5A, lane 4). Stimula-
tion of HCC70 cells with 17β-estradiol lead to a 170 ± 20%expression of cyclin D1 (p < 0.01) (Figure 5B, lane 2), that
was completely abolished by pretreatment with 10−4 M
estriol (Figure 5B, lane 4).
Aromatase expression in TNBC cells
Aromatase, an enzyme necessary for synthesis of 17β-
estradiol, was reported to be GPR30 dependently regulated
[20]. RT-PCR analysis of the mRNA of TNBC cell lines
revealed an extraordinary high expression of aromatase in
HCC1806 cells (Figure 5A). This high expression of aro-
matase was further increased to 130% after treatment with
10−8 M 17β-estradiol. In HCC70 cells expressing much
less aromatase (Figure 5B, lane 1) estradiol significantly
stimulated expression of aromatase to 120 ± 5% (p < 0.05)
(Figure 5B, lane 2). A further TNBC cell line tested
(MDA-MB-435) showed a more pronounced induction of
aromatase to 180 ± 20% (p < 0.01) of control after stimula-
tion with 10−8 M 17β-estradiol (data not shown). In all
three cell lines pretreatment with 10−4 M estriol blocked
estradiol-induced stimulation of aromatase expression
(Figure 5A and B, lane 4).
Gα-dependent signaling of GPR30
Phosphorylation of CREB-protein
Activation of GPR30 by its ligands, 17β-estradiol, 4-
Hydroxytamoxifen or Fulvestrant releases of Gα from
the heterotrimeric G-protein complex after ligand binding
and further initiates activation of adenylyl cyclase PKA
and phosphorylation of the cAMP-responsive element
binding protein CREB [21]. Phosphorylation of CREB after
stimulation of TNBC cells with 17β-estradiol was analyzed
using Western blot technology (Figure 6).
Two protein bands at 35 kD and 40 kD became visible
in the variously treated samples using a phospho-Ser133-
CREB antibody (Cell Signaling, Boston, MA). According
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Figure 4 Disruption of signal transduction of GPR30 in TNBC cell lines. Western blots (A) HCC1806 and (B) HCC70. Serum starved cells
(lane 1) were stimulated for five minutes with 10−8 M 17β-estradiol (lane 2) or pretreated for 30 minutes with 10−4 M estriol E3 (lane 3) and E3
treated cells were subsequently stimulated with 10−8 M 17β-estradiol (lane 4). Cells were lysed, proteins separated in a polyacrylamide gel, blotted
onto a PVDF-membrane, and the indicated proteins were sequentially detected with antibodies against phospho-src (panel 1), total-src (panel 2),
phospho-EGF-receptor (panel 3), total EGF-receptor (panel 4), and actin, as housekeeping gene (panel 5). Representative results of three independent
preparations. (C) and (D) densitometric evaluation of Western blot results of p-src and pEGFR in HCC1806 cells (C) and HCC70 (D).
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phospho-ATF-1, a CREB-related protein, that gives rise
to the lower weight band [22]. Even in serum starved
cells of HCC1806 a substantial CREB phosphorylation was
detectable (Figure 6A, lane 1). Stimulation of HCC1806
cells with 10−8 M 17β-estradiol for 30 minutes led to a
slightly increased phosphorylation of CREB (Figure 6A, lane
2) Stimulation of HCC1806 cells resulted in an increase of
phosphorylated CREB to 220 ± 110% of control (Figure 6B,
lane 2). Pretreatment of the cells with 10−4 M estriol for 2hours lead to a slight decrease of phospho-CREB (Figure 6B,
lane 3). If HCC70 cells pretreated with estriol were subse-
quently stimulated with 10−8 M 17β-estradiol phosphoryl-
ation of CREB was clearly reduced even below control level
(Figure 6B, lane 4).
Estriol reduces binding of CREB protein to the promoter
of cyclin D1
Phosphorylated CREB binds to the cAMP responsive
elements in promoters of genes and initiates their
-E2 +E2     -E2 +E2  
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Figure 5 Prevention of gene expression by inhibition of GPR30 with estriol. RT-PCR of (A) HCC1806 and (B) HCC70 Serum starved cells of
TNBC cell lines (lane 1) were stimulated for 30 minutes with 10−8 M 17β-estradiol (lane 2) or pretreated with 10−4 M estriol (lane 3) and subsequently
stimulated with 10−8 M 17β-estradiol (lane 4). mRNA was extracted, transcribed to cDNA and amplified by PCR using primers specific for c-fos (panel
1), cyclin D1 (panel 2) or aromatase (panel 3). L7, a ribosomal housekeeping gene, was amplified to prove the presence of equal amounts of RNA in
each PCR reaction of the respective cell line (panel 4). Representative results of three separate experiments. (C) and (D) densitometric evaluation of
RT-PCR results of c-fos, cyclin D1 and aromatase in HCC1806 cells (C) and HCC70 (D).
Girgert et al. BMC Cancer 2014, 14:935 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/935transcription. To study the influence of 17β-estradiol on
binding of phosphorylated CREB to CRE of the cyclin D1
promoter nuclear proteins were purified from estradiol
stimulated HCC1806 and HCC70 cells and used for an
electrophoretic mobility shift assay (Figure 7).
The non-bound oligonucleotides were moving at the
front of the gel in all samples. There is a clearly visible
band of the biotin-labeled oligonucleotide probe con-
taining a CRE from the cyclin D1 promoter at about 50
kD in all lanes except lane 5, where a 100-fold excess of
unlabeled probe was additionally added to the nuclear
proteins. Even in serum starved cells a weak shifted bandwas detected (Figure 7, lane 1). In HCC1806 cells stimu-
lated with 10−8 M 17β-estradiol the intensity of the shifted
band increased on average to 161 ± 59% (Figure 7A, lane
2) and 320 ± 170% of control in HCC70 cells (Figure 7B,
lane 2), whereas in HCC70 cells pretreated with estriol the
CREB-signal was only 30% stronger than in serum starved
cells after stimulation with 17β-estradiol (Figure 7B, lane
4). Besides the band at 40 kD specific for CREB an
additional shifted band occur on the blotted gel at about
150 kD that is either shifted by other unknown nuclear
proteins or shifted by CREB additionally complexed with
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C
Figure 6 Phosphorylation of CREB protein in TNBC cells. HCC1806 cells (A) and HCC70 cells (B) serum starved for 24 h (lane 1) were stimulated
for 30 minutes with 10−8 M 17β-estradiol (lane 2) or pretreated for 30 minutes with 10−4 M estriol E3 (lane 3) and E3 treated cells were subsequently
stimulated for 30 minutes with 10−8 M 17β-estradiol (lane 4). Cells were lysed, proteins separated in a polyacrylamide gel, blotted onto a
PVDF-membrane and phospho-CREB and total CREB proteins were sequentially detected with according antibodies. Representative results
of three independent preparations. (C) densitometric evaluation of Western blots results of CREB phosphorylation under various conditions
normalized to total CREB expression in HCC1806 cells and HCC70.
HCC70















Figure 7 Electrophoretic mobility shift of a cAMP responsive element from cyclin D1 promoter. Cells of TNBC cell line HCC1806 (A) or of
cell line HCC70 (B) were serum starved (lane 1) and either stimulated for 15 minutes with 10−8M 17β-estradiol (lane 2), or pretreated for 30 minutes
with 10−4 M estriol (lane 3) before they were stimulated with 10−8M 17β-estradiol for further 15 minutes (lane 4). Cells were harvested and nuclear
proteins purified from the cell pellets were incubated with the cyclin D1 specific oligonucleotide probe for 20 minutes at room temperature. After
binding reaction the mixture was separated on a 6% non-denaturing polyacrylamide gel, blotted onto a nylon membrane and the biotin-labeled
probe was detected using HRP-labeled streptavidin. To prove specificity of reaction a control containing a 100-fold excess of unlabeled oligonucleotide
was added to a second estradiol-treated sample (lane 5) and for supershift (S) 1 μl phospho-CREB antibody was added (lane 6). Representative
EMSA-assay of three independent experiments.
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formed using an oligonucleotide representing a DNA-
sequence of a CRE detected further upstream of the
above mentioned CRE at position -517 to -493. In none
of the TNBC cell lines we observed a shifted band of this
upstream CRE after stimulation of the cells with 10−8 M
17β-estradiol (data not shown).
Discussion
TNBC is characterized by the lack of expression of
estrogen receptor α (ERα) and progesterone receptors
and no overexpression of Her-2. This makes these tumors
refractory for standard antiestrogen therapy with Tamoxi-
fen and for antibody therapy using Trastuzumab. GPR30,
a membrane-bound receptor for estrogens responsible
for fast non-genomic effects of 17β-estradiol, might be
a promising target in TNBC. Immunohistochemical
staining of sections of a small cohort of TNBCs for
GPR30 revealed that most of these tumors strongly
expressed GPR30. GPR30 expression correlated with a
higher recurrence rate of TNBC [8]. Experimentally, it has
been shown that 17β-estradiol also induces proliferation
in immortalized breast epithelial cell line MCF10A in a
GPR30-dependent manner as well as does the GPR30-
specific agonist G1 [23]. Only recently, we have used
GPR30 specific siRNA to knock-down GPR30 expression
in TNBC making the treated cells refractory to growth
stimulation by 17β-estradiol [12]. There are meanwhile a
number of clinical investigations discussing an involve-
ment of GPR30 in malignant transformation of breast
cancer cells [24-26]. In addition, GPR30 was found to play
a growth promotion role in ovarian cancer [27]. All
these observations strongly support our assumption
that stimulation of GPR30 by circulating 17β-estradiol
contributes to the malignant behavior of TNBC. GPR30
was also expressed in the TNBC cell lines used in the
present study, except MDA-MB-231 that were used as
negative control (Figure 2B and D). Stimulation of TNBC
cell lines with the ligands of GPR30, 17β-estradiol and 4-
Hydroxy-tamoxifen leads to activation of src-kinase and
EGF-receptor phosphorylation. Recently we reported that
knock-down of GPR30 expression using siRNA com-
pletely prevented activation of these kinases and abrogated
the stimulation of cell proliferation by 17β-estradiol in
TNBC cell lines [12]. Therefore, a search for potent
pharmacological inhibitor of GPR30 might prove valuable
for the treatment of TNBC.
G15, a substance from a compound library, was re-
ported to be selective for GPR30 and inhibited signal
transduction of GPR30 [14]. The naturally occurring
estrogen metabolite estriol has also been shown to be a
GPR30 antagonist in estrogen receptor-negative breast
cancer cell line SKBr3 [15]. SKBr3 is not a representative
of TNBC cell lines, because this cell line overexpressesHer-2. But as we show in the present report, estriol is a
potent GPR30 antagonist in a number of TNBC cell
lines. Treatment of TNBC cell lines with estriol led to a
significant reduction in cell number to 16% of control at
8×10−5 M estriol, the highest concentration achievable
in aqueous solution. The inhibitory effect of estriol on
cell proliferation correlated with the amount of GPR30
expressed in the various TNBC cell lines.
Phosphorylation of src-kinase and transactivation of
EGF-receptor by 17β-estradiol were almost as successfully
prevented as was observed after knock-down of GPR30
using siRNA [12]. In addition to the inhibition of EGF-
receptor activation, estriol also proved to be effective
against the Gα-dependent signaling of GPR30. Phosphor-
ylation of the cAMP-responsive element binding protein
(CREB) by PKA was already prominent in the absence
of17β-estradiol implying that in addition PKA is activated
by other signaling pathways, too. ATF1, a relative to
CREB, is phosphorylated almost to the same extent as
CREB after stimulation of TNBC cells with 17β-estradiol.
This phosphorylation is even more clearly prevented by
the pretreatment with 10−4 M estriol.
Electrophoretic shift assays (EMSAs) were performed
with a labeled oligonucleotide representing the CRE in
the promoter of the cyclin D1 promoter at position -14
to +11 from the transcription start site. In TNBC cells
treated with 10−8 M 17β-estradiol an oligonucleotide
band shifted by about 40 kD increased in intensity. In
cells pretreated with 10−4 M estriol the amount of
shifted oligonucleotide was lower than in cells treated
with 17β-estradiol alone. Again, this finding provides
evidence, that induction of cyclin D1 expression by
17β-estradiol is GPR30 dependent and prevented by
estriol treatment. EMSAs showed an additional band at
about 150 kD that was detectable in all samples inde-
pendent of the various treatments of the TNBC cells.
The origin of this band is not yet clear. In supershift
experiments using an antibody against phosphorylated
CREB this band disappeared from the blot because it
was shifted to much higher molecular weight. By this
supershift experiment this unknown additional band in
EMSAs is at least identified to contain CREB. This
band probably arises from CREB complexed with other
proteins bound to the oligonucleotide of the cyclin D1
promoter.
Using an oligonucleotide with CRE found further up-
stream at position –517 to –493 we did not observe a
binding of CREB to this oligonucleotide at any treatment
condition (data not shown).
RT-PCR examinations of mRNA from estriol/estradiol
treated cells for cyclin D1 expression confirmed the re-
sults of the CREB binding to a cAMP-responsive element
of the cyclin D1 promoter, as observed in EMSA tests
(Figure 7). All the above mentioned results clearly indicate
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TNBC by 17β-estradiol.
In addition, we analyzed the GPR30 dependent regula-
tion aromatase expression in TNBC cells. Treatment with
17β-estradiol induced aromatase expression in TNBC cell
lines and estriol prevented this induction completely
(Figure 5). The induction of aromatase expression by 17β-
estradiol is in accordance with a report of Lin et al. [20]
who observed a novel signaling paradigm in endometrial
cancer cells initiated by estrogenic activation of GPR30.
They showed that PI3K and MAPK signal transduction
cascades activated by GPR30 converge on nuclear hor-
mone receptor SF-1 that modulates transcription of the
aromatase gene [20]. This novel GPR30/SF-1 pathway
increases local concentrations of estrogen, and mediates
autocrine proliferative effect on cells expressing GPR30.
We hypothesize, that in TNBC cells, an autocrine
circuit of 17β-estradiol exists that upregulates its own
synthesis via stimulation of GPR30. In detail, 17β-estradiol
stimulates aromatase expression via GPR30 and the
additionally synthesized 17β-estradiol further stimulates
GPR30 exponentially leading to growth stimulation of the
TNBC cells. Estriol is capable to disrupt this vicious circle
by inhibition of GPR30 as we were able to show that
induction of aromatase expression by 17β-estradiol is
suppressed by treatment with 10−4 M estriol. As final
consequence of inhibition of GPR30 activity growth
stimulation of TNBC cells by 17β-estradiol is clearly
prevented by estriol.
High plasma levels of estriol are detected during preg-
nancy and women who were multiparous have a more
than one-third lower risk of breast cancer [28]. The re-
duced risk for basal-like breast cancer, the major form of
TNBC, observed in women with increasing number of
breastfed children might be an additional indication for
a protective effect of estriol for TNBC [29]. But it should
be considered, that serum-levels at the third trimester of
pregnancy were estimated to be at 4×10−8 M [30] and
this is a 1000 times lower concentration than we applied
in the proliferation assay of TNBC cell lines.
Due to its limited solubility in culture medium the
effects of estriol could not be further increased. The syn-
thetic GPR30 antagonist G15 was even less soluble in cul-
ture medium (maximal solubility 10−5 M) and therefore
less effective in inhibiting EGF-receptor transactivation
(data not shown) and less effective in prevention of prolif-
eration (see Additional file 2).
Other GPR30 antagonists are presently under investiga-
tion in several laboratories. In 2011, Dennis et al. de-
scribed another GPR30 antagonist (G36) having a slightly
higher affinity to GPR30 than G15 but no information on
the aqueous solubility of this compound was given by the
authors [14]. Lappano et al. [31] introduced MIBE, an in-
hibitor, that acts on both GPR30 and estrogen receptor α[31]. Further a tricarbonyl-Re/Tc(I) chelate with GPR30
antagonistic properties has been described [32]. All these
compounds are worth testing their efficiency on TNBC.
While measuring the effects of estriol on GPR30 in
TNBC cell lines we were aware that besides ERα and
GPR30 (GPER) there is a third receptor for estrogens,
ERβ, in many different cell types. In addition, it is fre-
quently described, that ERβ is an opponent of ERα, and
from our results we cannot certainly reason that the in-
hibitory action of estriol in TNBC is solely exerted by
GPR30. But Western blots of proteins from our tested
cell lines revealed a very low expression of ERβ in these
cell lines (see Additional file 3: Figure S3).
Up to now, no targeted therapy for TNBC was shown
to be successful. Promising candidates, like PARP inhibi-
tors, taking advantage of a disturbed DNA-repair due to
frequent BRCA1-mutations present in TNBC [3,4] and
the use of the EGF-R antibody Cetuximab for therapy
targeting the overexpression of the EGF-receptor in
TNBC were of limited success [2-4].
Our observation, that growth of TNBC is stimulated
by 17β-estradiol via GPR30 indicates that reduction of
17β-estradiol in TNBC patients by application of aroma-
tase inhibitors might remain a therapeutic option in
triple-negative breast cancer. The efficacy of estriol in
inhibiting proliferation of TNBC cells should be further
evaluated in vivo.
Conclusions
In principle we were able to show that GPR30 is involved
in growth stimulation of triple-negative breast cancer by
17β-estradiol. Estriol effectively inhibited signal transduc-
tion of GPR30 and successfully prevented growth promo-
tion by 17β-estradiol. These results clearly show that a
pharmacological inhibition of GPR30 is a promising tar-
geted treatment option for triple-negative breast cancer.
The concentrations of estriol needed for sufficient growth
inhibition are unfortunately unphysiologically high. There is
a need for developing more effective inhibitors for GPR30.
Additional files
Additional file 1: Figure S1. Growth curves of HCC1806 cells in
dependence of 17β-estradiol. HCC1806 cells were grown in phenolred-free
medium supplemented with 10% charcoal stripped serum for one to seven
days (•) control or in the presence of 10
−10 M 17β-estradiol (■) or in the
presence of 10-9 M 17β-estradiol (▲). Cells were counted under each
condition on day 1; day 2; day 4 and day 7 and related to the cell number
(100%) seeded to the six-well plates. The minimal growth of HCC1806 cells
in the medium without 17β-estradiol is probably due to growth factors like
EGF etc present in the charcoal stripped serum.
Additional file 2: Figure S2. Inhibition of growth of HCC1806 cells by
GPR30 antagonist G15. HCC1806 cells were grown in phenolred-free
medium supplemented with 10% charcoal stripped serum in the presence
of increasing concentrations of G15 for 7 days and relative cell number was
estimated using colorimetric Alamarblue assay. Aqueous solubility of G15
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(2x10−6 M – 2x10−5 M) slightly increased cell growth compared to control in
the presence of 4x10−5 M G15 cell number of HCC1806 was significantly
reduced to about 40% of control. Growth inhibition by G15 could not be
further increased due to solubility limits.
Additional file 3: Figure S3. Expression of three different receptors for
17β-estradiol in breast cancer cell lines. Western blots of 20 μg protein of
four breast cancer cell lines were sequentially analyzed with antibodies
for ERα, ERβ and GPR30. All three antigens were highly expressed in
MCF-7 cells. Expression of ERα was strong in MCF-7, weak in HCC70 and
non-detectable in HCC1806 and MDA-MB-453. ERβ was highly expressed
in MCF-7 and negligible in HCC1806, HCC70 and MDA-MB-453. GPR30
expression was visible in all four cell lines.
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